Effects of miR-515-5p on the proliferation and metastasis of ovarian cancer cell A2780 by regulating the expression of chondroitin sulfate proteoglycan 4 and its mechanism

JIANG Hong; HUANG Yan-Li; XING Hui; WANG Li-Ming; GUO Hong

doi:10.16098/j.issn.0529-1356.2022.01.006

PDF(11747 KB)

Acta Anatomica Sinica ›› 2022, Vol. 53 ›› Issue (1) : 42-49. DOI: 10.16098/j.issn.0529-1356.2022.01.006

Effects of miR-515-5p on the proliferation and metastasis of ovarian cancer cell A2780 by regulating the expression of chondroitin sulfate proteoglycan 4 and its mechanism

JIANG Hong¹ HUANG Yan-li¹ XING Hui¹ WANG Li-ming² GUO Hong^1*

Author information +

History +

Abstract

Objective To investigate the targeted regulation of miR-515-5p on chondroitin sulfate proteoglycan 4 (CSPG4) and its effect on the proliferation and metastasis of ovarian cancer cell A2780. Methods The target genes of miR-515-5p were predicted by bioinformatics tools. Real-time PCR and Western blotting were used to detect the expression of miR-515-5p and CSPG4 in 65 cases ovarian cancer tissues and adjacent tissues. Ovarian cancer cells A2780 were divided into miR-NC group, miR-515-5p group, si-NC group, si-CSPG4 group, miR-515-5p + pcDNA group, miR-515-5p + pcDNA-CSPG4 group. MTT assay was used to detect cell proliferation. Transell was applied to detect cell migration and invasion, and Western blotting was selected to detect cyclinD1, P21, matrix metalloproteinase(MMP)-2 and MMP-9 protein expression. The double luciferase reporter gene experiment and Western blotting confirmed the regulation effect of miR-515-5p on CSPG4 gene. Results Bioinformatics analysis showed that CSPG4 was one of the potential target genes of miR-515-5p. Compared with the adjacent tissues, the expression of miR-515-5p was lower in ovarian cancer tissues, and the expression of CSPG4 was higher (P<0.05). Compared with the miR-NC group, the expression of cyclinD1, MMP-2 and MMP-9 protein was lower in A2780 cells of miR-515-5p group, the expression of P21 protein was higher, the cell viability was lower, and the number of cell migration and invasion was lower (P<0.05). Compared with the si-NC group, the expression of cyclinD1, MMP-2 and MMP-9 proteins were lower in A2780 cells in si-CSPG4 group, P21 protein was higher, cell viability was lower, and the number of cell migration and invasion was lower (P<0.05). Compared with the miR-515-5p + pcDNA group, the expression of cyclinD1, MMP-2 and MMP-9 proteins was higher in A2780 cells of miR-515-5p + pcDNA-CSPG4 group, the expression of P21 protein was lower, and the cell viability was higher, the number of cell igration and invasion was higher (P<0.05). MiR-515-5p targeted and negatively regulated CSPG4 expression. Conclusion MiR-515-5p could inhibit the proliferation and metastasis of ovarian cancer cell A2780 by targeting CSPG4.

Key words

Ovarian cancer / MicroRNA-515-5p / Chondroitin sucfac proteoglycan 4 / Cell proliferation / Metastasis / Transwell assays / Human

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

JIANG Hong HUANG Yan-li XING Hui WANG Li-ming GUO Hong. Effects of miR-515-5p on the proliferation and metastasis of ovarian cancer cell A2780 by regulating the expression of chondroitin sulfate proteoglycan 4 and its mechanism[J]. Acta Anatomica Sinica. 2022, 53(1): 42-49 https://doi.org/10.16098/j.issn.0529-1356.2022.01.006

References

1］ Kroeger PT Jr, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer［J］. Curr Opin Obstet Gynecol, 2017, 29(1): 26-34.

［2］ Siegel RL, Miller KD, Jemal A, et al. Cancer statistics, 2017［J］. CA Cancer J Clin, 2017, 67(1): 7-30.

［3］ Deb B, Uddin A, Chakraborty S. miRNAs and ovarian cancer: an overview［J］. J Cell Physiol, 2018, 233(5): 3846-3854.

［4］ Zhang X, Zhou J, Xue D, et al. MiR-515-5p acts as a tumor suppressor via targeting TRIP13 in prostate cancer［J］. Int J Biol Macromol, 2019, 129(1): 227-232.

［5］ Qiao K, Ning S, Wan L, et al. LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway［J］. J Exp Clin Cancer Res, 2019, 38(1): 418.

［6］ Nicolosi PA, Dallatomasina A, Perris R. Theranostic impact of NG2/CSPG4 proteoglycan in cancer［J］. Theranostics, 2015, 5(5): 530-544.

［7］ Ye MH. CSPG4 promotes the proliferation and migration of epithelial ovarian cancer cells through c-Met and ERK1/2［D］. Hu’nan Hengyang: Nanhua University, 2018. (in Chinese)

叶迈豪. CSPG4通过c-Met和ERK1/2促进上皮性卵巢癌细胞增殖与迁移的研究［D］. 湖南衡阳：南华大学, 2018.

［8］ Suzuki HI, Katsura A, Matsuyama H, et al. MicroRNA regulons in tumor microenvironment［J］. Oncogene, 2015, 34(24): 3085-3094.

［9］ Gilam A, Edry L, Mamluk-Morag E, et al. Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers［J］. Breast Cancer Res Treat, 2013, 138(3): 753-760.

［10］ Pardo OE, Castellano L, Munro CE, et al. miR-515-5p controls cancer cell migration through MARK4 regulation［J］. EMBO Rep, 2016, 17(4): 570-584.

［11］ Pinho FG, Frampton AE, Nunes J, et al. Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation［J］. Cancer Res, 2013, 73(19): 5936-5948.

［12］ Zhang H, Wang X, Huang H, et al. Hsa_circ_0067997 promotes the progression of gastric cancer by inhibition of miR-515-5p and activation of X chromosome-linked inhibitor of apoptosis (XIAP)［J］. Artif Cells Nanomed Biotechnol, 2019, 47(1): 308-318.

［13］ Li J, Tang Z, Wang H, et al. CXCL6 promotes non-small cell lung cancer cell survival and metastasis via down-regulation of miR-515-5p［J］. Biomed Pharmacother, 2018, 97(1): 1182-1188.

［14］ Nicolosi PA, Dallatomasina A, Perris R. Theranostic impact of NG2/CSPG4 proteoglycan in cancer［J］. Theranostics, 2015, 5(5): 530-544.

［15］ Winship A, Van Sinderen M, Heffernan-Marks A, et al. Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration［J］. Int J Oncol, 2017, 50(3): 798-804.

［16］ Kang J, Li ZY, Chen L, et al. Research progress of CSPG4/NG2 in immunosuppressive therapy of glioma［J］. Chinese Journal of Minimally Invasive Neurosurgery, 2017, 22(1): 46-48. (in Chinese)

康剑, 李宗阳, 陈垒, 等. CSPG4/NG2在胶质瘤免疫抑制治疗中的研究进展［J］. 中国微侵袭神经外科杂志, 2017, 22(1): 46-48.

［17］ Chen Y. Expression of CSPG4 in epithelial ovarian cancer and its clinical significance［D］. Hu’nan Hengyang: Nanhua University, 2018. (in Chinese)

陈嫣. CSPG4在上皮性卵巢癌组织中的表达及其临床意义［D］. 湖南衡阳：南华大学, 2018.

［18］ Sun J. Expression of CSPG4 in pancreatic cancer and its correlation with prognosis［D］. Chongqing: Third Military Medical University, 2015. (in Chinese)

孙靖. CSPG4在胰腺癌中的表达及其与预后相关性的研究［D］. 重庆：第三军医大学, 2015.